EUVIMEDEUVIMED entdecken
Crossref

Impact of non‐selective beta blockers on further decompensation and death in decompensated cirrhosis: Benefit and risk stratification by MELD score

Ting Wang, Xueying Wang, Siqi Jia, Haitao Zhao, Le Wang, Xianxian Zhang, Xiaohui Fang, Yong He, Hongyu Li, Frank Tacke iD, Xingshun Qi iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Ting Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, General Hospital of Northern Theater Command (Teaching Hospital of Shenyang Pharmaceutical University), Shenyang, Chi…. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Liver Cirrhosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: the Outstanding Youth Foundation of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non‐selective beta blockers (NSBBs) can reduce the risk of decompensation, but their impact on further decompensation has been rarely investigated.

Aims

The aim is to evaluate the impact of NSBBs on further decompensation and death in decompensated cirrhosis stratified by the severity of liver disease.

Methods

Overall, 332 decompensated cirrhotic patients were retrospectively included, of whom 149 used NSBBs. Kaplan–Meier and Nelson–Aalen cumulative risk curves as well as Cox regression and competing risk analyses were used to estimate the associations of NSBBs with further decompensation and death, if appropriate. Hazard ratio (HR) and sub‐distribution HR (sHR) were calculated. Subgroup analyses were performed based on the model for end‐stage liver disease (MELD) score at admission.

Results

In the overall analysis, the use of NSBBs was not significantly associated with further decompensation in multivariate competing risk analysis (sHR = 1.09, p = 0.580). In the subgroup analysis of patients with a MELD score of ≤9, the use of NSBBs was significantly associated with decreased risk of further decompensation in multivariate competing risk analysis (sHR = 0.57, p = 0.021). In the subgroup analysis of patients with a MELD score of >9, the use of NSBBs was associated with increased risk of further decompensation in multivariate competing risk analysis (sHR = 1.45, p = 0.044). Regardless of overall and subgroup analyses, the use of NSBBs was not significantly associated with death in multivariate Cox regression analyses.

Conclusion

NSBBs may be beneficial for the prevention of further decompensation in cirrhotic patients with a MELD score of ≤9, but deleterious in those with a MELD score of >9.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-AntagonistsLiver CirrhosisAdultAgedFemaleHumansMaleMiddle AgedEnd Stage Liver DiseaseKaplan-Meier EstimateProportional Hazards ModelsRetrospective StudiesRisk AssessmentSeverity of Illness Index

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Department of Gastroenterology, General Hospital of Northern Theater Command (Teaching Hospital of Shenyang Pharmaceutical University), Shenyang, China.
  • Department of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.
  • Postgraduate College, Jinzhou Medical University, Jinzhou, China.
  • Medical Ethical Committee, General Hospital of Northern Theater Command, Shenyang, China.
  • Postgraduate College, China Medical University, Shenyang, China.
  • Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany.

ORCID-Profile: Frank Tacke, Xingshun Qi

Förderung

  • the Outstanding Youth Foundation of Liaoning Province

Zitieren

APA

Wang, T., Wang, X., Jia, S., Zhao, H., Wang, L., Zhang, X., Fang, X., He, Y., Li, H., Tacke, F., & Qi, X. (2024). Impact of non‐selective beta blockers on further decompensation and death in decompensated cirrhosis: Benefit and risk stratification by MELD score. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18261

Vancouver

Wang T, Wang X, Jia S, Zhao H, Wang L, Zhang X, et al. Impact of non‐selective beta blockers on further decompensation and death in decompensated cirrhosis: Benefit and risk stratification by MELD score. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18261

BibTeX
@article{Wang2024,
  author = {Wang, Ting and Wang, Xueying and Jia, Siqi and Zhao, Haitao and Wang, Le and Zhang, Xianxian and Fang, Xiaohui and He, Yong and Li, Hongyu and Tacke, Frank and Qi, Xingshun},
  title = {Impact of non‐selective beta blockers on further decompensation and death in decompensated cirrhosis: Benefit and risk stratification by MELD score},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18261}
}
Kostenlos starten →